Treatment outcomes of pregnant women with drug-resistant tuberculosis in Uganda: A retrospective review of 18 cases
Background: There is a dearth of reports on drug-resistant tuberculosis (DRTB) treatment outcomes among pregnant women in tuberculosis (TB)/HIV high-burdened countries. We report treatment outcomes of 18 pregnant women with DRTB in Uganda. Methods: We reviewed charts of individuals who received DRTB...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-04-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971221001181 |
| _version_ | 1818607379773652992 |
|---|---|
| author | Joseph Baruch Baluku Felix Bongomin |
| author_facet | Joseph Baruch Baluku Felix Bongomin |
| author_sort | Joseph Baruch Baluku |
| collection | DOAJ |
| description | Background: There is a dearth of reports on drug-resistant tuberculosis (DRTB) treatment outcomes among pregnant women in tuberculosis (TB)/HIV high-burdened countries. We report treatment outcomes of 18 pregnant women with DRTB in Uganda. Methods: We reviewed charts of individuals who received DRTB treatment in Uganda across 16 DRTB treatment sites. We included all women who were pregnant during DRTB treatment and had a treatment outcome documented between 2013 and 2019. Results: There were 18 pregnant women with a mean age (standard deviation (SD)) of 27.5 (5.2) years, of whom 8 (44.4%) were HIV co-infected. Among these women, 12 (66.7%) had primary DRTB and 8 (44.4%) had multidrug-resistant TB. Levofloxacin (Lfx), Pyrazinamide, Cycloserine and Kanamycin (Kn) were the most (>78%) used drugs in the treatment regimen and the mean (SD) treatment duration was 17.6 (7.5) months. Elevated liver enzymes (81.8%, n = 11) and hearing loss (33.3%, n = 15) were the most frequently encountered drug adverse events. Treatment success was observed among 15 (83.3%) patients, 2 (11.1%) patients were lost to follow up and 1 (5.6%) patient died. Conclusion: The treatment success among pregnant women with DRTB in Uganda was high despite a high prevalence of HIV co-infection. |
| first_indexed | 2024-12-16T14:25:49Z |
| format | Article |
| id | doaj.art-b347a59b22cf4c0199db32f85b2a7dea |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-12-16T14:25:49Z |
| publishDate | 2021-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-b347a59b22cf4c0199db32f85b2a7dea2022-12-21T22:28:22ZengElsevierInternational Journal of Infectious Diseases1201-97122021-04-01105230233Treatment outcomes of pregnant women with drug-resistant tuberculosis in Uganda: A retrospective review of 18 casesJoseph Baruch Baluku0Felix Bongomin1Mulago National Referral Hospital, Kampala, Uganda; Makerere University Lung Institute, Kampala, Uganda; Mildmay Uganda, Wakiso, Uganda; Corresponding author at: PO Box 26343, Kampala, Uganda.Gulu University, Gulu, UgandaBackground: There is a dearth of reports on drug-resistant tuberculosis (DRTB) treatment outcomes among pregnant women in tuberculosis (TB)/HIV high-burdened countries. We report treatment outcomes of 18 pregnant women with DRTB in Uganda. Methods: We reviewed charts of individuals who received DRTB treatment in Uganda across 16 DRTB treatment sites. We included all women who were pregnant during DRTB treatment and had a treatment outcome documented between 2013 and 2019. Results: There were 18 pregnant women with a mean age (standard deviation (SD)) of 27.5 (5.2) years, of whom 8 (44.4%) were HIV co-infected. Among these women, 12 (66.7%) had primary DRTB and 8 (44.4%) had multidrug-resistant TB. Levofloxacin (Lfx), Pyrazinamide, Cycloserine and Kanamycin (Kn) were the most (>78%) used drugs in the treatment regimen and the mean (SD) treatment duration was 17.6 (7.5) months. Elevated liver enzymes (81.8%, n = 11) and hearing loss (33.3%, n = 15) were the most frequently encountered drug adverse events. Treatment success was observed among 15 (83.3%) patients, 2 (11.1%) patients were lost to follow up and 1 (5.6%) patient died. Conclusion: The treatment success among pregnant women with DRTB in Uganda was high despite a high prevalence of HIV co-infection.http://www.sciencedirect.com/science/article/pii/S1201971221001181Drug-resistant tuberculosisMDR TBPregnancyUgandaHIVWomen |
| spellingShingle | Joseph Baruch Baluku Felix Bongomin Treatment outcomes of pregnant women with drug-resistant tuberculosis in Uganda: A retrospective review of 18 cases International Journal of Infectious Diseases Drug-resistant tuberculosis MDR TB Pregnancy Uganda HIV Women |
| title | Treatment outcomes of pregnant women with drug-resistant tuberculosis in Uganda: A retrospective review of 18 cases |
| title_full | Treatment outcomes of pregnant women with drug-resistant tuberculosis in Uganda: A retrospective review of 18 cases |
| title_fullStr | Treatment outcomes of pregnant women with drug-resistant tuberculosis in Uganda: A retrospective review of 18 cases |
| title_full_unstemmed | Treatment outcomes of pregnant women with drug-resistant tuberculosis in Uganda: A retrospective review of 18 cases |
| title_short | Treatment outcomes of pregnant women with drug-resistant tuberculosis in Uganda: A retrospective review of 18 cases |
| title_sort | treatment outcomes of pregnant women with drug resistant tuberculosis in uganda a retrospective review of 18 cases |
| topic | Drug-resistant tuberculosis MDR TB Pregnancy Uganda HIV Women |
| url | http://www.sciencedirect.com/science/article/pii/S1201971221001181 |
| work_keys_str_mv | AT josephbaruchbaluku treatmentoutcomesofpregnantwomenwithdrugresistanttuberculosisinugandaaretrospectivereviewof18cases AT felixbongomin treatmentoutcomesofpregnantwomenwithdrugresistanttuberculosisinugandaaretrospectivereviewof18cases |